Investigators evaluated children with acute lymphoblastic or acute myeloid leukemia to identify racial/ethnic and neighborhood disparities in acute kidney injury.

Fatigue is a key prognostic indicator for adverse outcomes in AML, ALL, and myelodysplastic syndromes. CAR T-cell therapy post-transplant shows a 48% complete remission rate in AML, though not ...

The FDA has approved INQOVI (decitabine and cedazuridine) plus venetoclax for newly diagnosed AML in adults aged 75 years or ...

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

Optimizing Blinatumomab Access for Low- and Middle-Income Countries: Feasibility of a Shortened, Vial-Sharing, Outpatient Approach for Pediatric ALL We retrospectively analyzed 473 adult patients with ...

Panelists discuss how future AML treatment will likely involve sophisticated decisions about triplet combinations, optimal sequencing of targeted agents, and balancing efficacy with toxicity through ...